A Phase I Study of Lipovaxin Tuberculosis Vaccine in Adult Healthy Populations

A Phase I, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate Safety and Immunogenicity of Lipovaxin Tuberculosis Vaccine (Bio Farma) in Healthy Populations Aged 18-40 Years in Indonesia

A Phase I, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate Safety and Immunogenicity of Lipovaxin Tuberculosis Vaccine (Bio Farma) in Healthy Populations Aged 18-40 Years in Indonesia

Study Overview

• Status: Not yet recruiting
• Conditions: Tuberculosis; TB Infection
• Intervention / Treatment: Biological: Placebo; Biological: LipovaxinS4-EAH (Middle Dose); Biological: LipovaksinS4-EAH (High Dose)

Detailed Description

The primary objectives of this trial is to assess the safety of Lipovaxin in adults aged 18-40 years while the secondary objectives are; (1) To assess the frequency of antigen-specific CD4 and CD8 T cell responses measured by expression of IFN-y, IL-2, or TNF-α between groups, and 2.) To assess serum changes in the levels of antigen-specific total IgG antibodies

Participants will be given two dose of 0.5 ml of Lipovaxin or control IM deltoid region of upper arm. A total of 60 participants will be recruited and randomized to either receive Medium-dose/ High-dose Lipovaksin or Control.

The recruitment will start with 6 sentinel participants, randomised to received mid dose or control vaccine. After evaluation of safety for mid dose of Lipovaksin TB, recruitment will be continued to recruit 24 participants to receive either mid dose or control vaccine. Additionally, 6 sentinel participants will also be recruited to receive either high dose or control vaccine. After evaluation of safety of high dose Lipovaksin TB, recruitment will be continued to recruit the 24 participants to receive either high dose or control vaccine.

All subjects will be evaluated for the local and systemic reactions and safety assessments in 30 minutes, 7 days and 28 days after 1st and 2nd injection. Additionally, the participants will be evaluated on the cellular and humoral immunogenicity in D0 and 14 days after 2nd dose of vaccination.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Phase 1

Contacts and Locations

Study Locations

• Indonesia
  • DKI Jakarta
    • Jakarta Pusat, DKI Jakarta, Indonesia, 10430
      • Cipto Mangunkusumo Hospital, Jl. Pangeran Diponegoro No. 71, Kenari, Jakarta Pusat, DKI Jakarta.
      • Principal Investigator: Sri R Hadinegoro
      • Sub-Investigator: Nina D Putri
      • Sub-Investigator: Robert Sinto
      • Sub-Investigator: Mira Yulianti
      • Sub-Investigator: Pratama Wicaksana

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria

1. Clinically Healthy participants aged 18-40 years;
2. Participants have been informed properly regarding the study and signed the informed consent form.
3. Participants will commit to comply with the instructions of the investigator and the schedule of the trial;
4. Participants must have a negative IGRA and sputum.
5. Clinically normal laboratory values for ureum, creatinine, SGOT, SGPT, complete blood count (CBC), urinalysis, coagulation test (PT, aPTT), total cholesterol, Globulin/Albumin ratio and CRP

Exclusion Criteria:

1. Those who are currently diagnosed with tuberculosis or have a history of tuberculosis (positive IGRA or GenXpert sputum test or chest Xray suggestive of TB) and/or history of tuberculosis treatment; including TB Preventive Treatment (TPT);
2. There are serious chronic diseases, or the disease is in the advanced stage that cannot be controlled smoothly, such as diabetes and thyroid disease;
3. Currently suffering from or within 2 years of any of the following serious diseases, such as: advanced tumor, autoimmune disease, progressive atherosclerosis, acute exacerbation of the chronic obstructive pulmonary disease, acute or progressive liver or kidney disease, congestive heart failure, etc.; based on interview with participants
4. Those with known or suspected (or high-risk) immune function impairments or abnormalities, such as those receiving more than 20mg/day of systemic glucocorticoids for 14 consecutive days within the last 4 weeks, immunosuppressants within 3 months, and Those who received protein preparations or blood products or plasma extracts outside the gastrointestinal tract within 3 months;
5. People with allergic constitution, such as those with a history of allergy to two or more drugs or foods; a history of severe allergy to any component of the test vaccine, such as: anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenia Purpura, dyspnea, angioedema, etc.; or a history of the above-mentioned serious side effects after using any vaccine or drug in the past; history of bronchial asthma;
6. Current patients with HIV antibody positive for human immunodeficiency virus;
7. Women who are pregnant, breastfeeding, or have a positive urine pregnancy test during the screening period, or before vaccination, or who have childbearing plans during the study period;
8. Subjects receive any vaccination within 1 month before and after dosing;
9. Those who have participated in any other clinical research and used the investigational drug within 3 months before this clinical research;
10. Any other situation that the researcher believes may affect the evaluation of the research.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Control; NacL 0.9%	Biological: Placebo; 0,5 mL of Placebo containing NaCl 0.9%. Administered twice, 28 days apart
Experimental: Middle Dose; Middle Dose (20 ug) LipovaxinS4-EAH	Biological: LipovaxinS4-EAH (Middle Dose); 0,5 mL of Middle Dose LipovaxinS4-EAH. Administered twice, 28 days apart
Experimental: High Dose; High Dose (25 ug) LipovaxinS4-EAH	Biological: LipovaksinS4-EAH (High Dose); 0,5 mL of HIgh Dose LipovaxinS4-EAH. Administered twice, 28 days apart

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Local and systemic reactions	Local reactions and systemic events 30 minutes, 7 days and 28 days after 1st and 2nd dose of Vaccine/Placebo (additional 14 days after 1st dose for sentinel group)	30 minutes, 7 days and 28 days after 1st injection and 2nd injection for all group, and 30 minutes, 7 days and 28 days after 1st injection and 2nd injection and 14 days after 1st dose for sentinel group
Any AEs and SAEs	Any Adverse Events (AEs) and Serious Adverse Events (SAEs)	until 6 months after 2nd injection
Laboratory changes	Laboratory changes in D0, 14 days after 1st dose (sentinel group) and 28 days after 2nd dose.	D0, 14 days after 1st injection (sentinel), 28 days after 2nd injection

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cellular Immunogenicity	Intracellular cytokine staining of antigen specific T-cells (IFN-y, IL-2, or TNF-α) in D0 and 14 days after 2nd dose	D0 and 14 days after 2nd dose.
Humoral Immunogenicity	Geometric mean time (GMT), seropositive, seroconversion of total serum IgG antigen specific in D0 and 28 days after 2nd dose	D0 and 28 days after 2nd dose.

Collaborators and Investigators

• Sponsor: PT Bio Farma
• Collaborators: Dr Cipto Mangunkusumo General Hospital; Fakultas Kedokteran Universitas Indonesia

Study record dates

Study Major Dates

• Study Start (Estimated): August 1, 2026
• Primary Completion (Estimated): July 1, 2027
• Study Completion (Estimated): August 1, 2027

Study Registration Dates

• First Submitted: June 9, 2026
• First Submitted That Met QC Criteria: June 9, 2026
• First Posted (Actual): June 15, 2026

Study Record Updates

• Last Update Posted (Actual): June 15, 2026
• Last Update Submitted That Met QC Criteria: June 9, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: Tuberculosis; TB vaccine; Lipovaksin TB
• Additional Relevant MeSH Terms: Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Actinomycetales Infections; Mycobacterium Infections; Tuberculosis
• Other Study ID Numbers: TB-0125

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No